Kite, A Gilead Company
Clinical trials sponsored by Kite, A Gilead Company, explained in plain language.
-
First-of-its-Kind cell therapy trial aims to reset immune system in devastating nerve disorders
Disease control Not yet recruitingThis early-stage study is testing a new personalized cell therapy called KITE-363 for people with severe autoimmune nerve diseases that haven't responded to standard treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells that …
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New CAR-T therapy aims to outperform standard for Tough-to-Treat lymphoma
Disease control Not yet recruitingThis study aims to see if a new CAR-T cell therapy called KITE-753 works better than the currently approved therapy, axicabtagene ciloleucel, for adults with large B-cell lymphoma that has come back or didn't respond to their first treatment. It will enroll about 550 participants…
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC